机构:[1]Hebei Med Univ, Anim Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[2]Hebei Med Univ, Dept Rheumatol & Immuol, Hosp 4, Shijiazhuang, Hebei, Peoples R China临床科室免疫风湿科河北医科大学第四医院[3]Hebei Med Univ, Dept Hepatobiliary Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China临床科室肝胆外科河北医科大学第四医院[4]Hebei Med Univ, Basic Med Coll, Shijiazhuang, Hebei, Peoples R China
The expression of lysine methyltransferase SET8, which is involved in carcinogenesis of many types of human cancers through monomethylation of histone H4 lysine 20 (H4K20), is associated with the prognosis of hepatocellular carcinoma (HCC). We performed a functional analysis for SET8 to assess its effect on HCC progression. SET8 knockdown inhibited proliferation, migration and invasion of HCC cells. SET8 knockdown also inhibited tumour growth in a human xenograft mouse model. Overexpression of SET8 displayed the reverse effect, while treatment with the SET8 inhibitor UNC0379 produced an effect similar to SET8 knockdown. In addition, drug sensitivity testing in SET8-siRNA transfected HCC cells indicated that docetaxel inhibited cell growth dramatically, as demonstrated by the Cell Counting Kit-8 (CCK-8) assay. Furthermore, gene expression microarray analysis showed that genes altered after SET8 knockdown were clustered in pathways related to tumorigenesis and metastasis. Our data suggests that targeting SET8 for HCC therapy can inhibit the proliferation and invasion of HCC cells as well as increase their sensitivity to chemotherapy.
基金:
Natural Science Foundation of China of Hebei Province [H2019206428]; Science and Technology Project of Hebei [162777114D]